CYP19A1 and breast carcinoma: In conclusion, this study was consistent with the international phase III CONFIRM study and provides evidence for the efficacy of fulvestrant 500 mg in Chinese women with ER-positive advanced breast cancer whose disease had progressed or relapsed after prior endocrine therapy (antiestrogen or aromatase inhibitor).